Drs Gottschalk and Krenciute discuss the difficulties of translating successes with CAR T-cell therapy in adults to the pediatric population; ongoing research with investigational products that could reduce T-cell exhaustion, burnout, and the time from bench to bedside; and expectations for the future of cellular therapy in oncology.
Dr Ehrhardt discusses how modifiable chronic health conditions may relate to social determinants of health, noting how these factors can potentially lead to late mortality for survivors of childhood cancer.